Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
NCT04427709 · Wake Forest University Health Sciences · PHASE2 · terminated · last registry update 2026-10-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was initiated for preliminary data to support NIH grant submission. The study was maintained active in anticipation of returning to the protocol. Due to funding and current NIH grant work this study could not be completed.” | – | Registry record, Wake Forest University Health Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against OXTR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-06Also stopped (withdrawn): Florida State University, a drug against OXTR (NCT06710964)
- 2026-11-06Also stopped (withdrawn): Florida State University, a drug against OXTR (NCT06713473)
- 2026-11-03Results posted on the registry: University of California, Los Angeles, Oxytocin nasal spray + Placebo nasal spray (NCT03245437)
- 2026-10-26Also stopped (withdrawn): University of Roma La Sapienza, a drug against OXTR (NCT07010653)
- 2026-10-15Also stopped (terminated): University Hospital, Clermont-Ferrand, Oxytocin + Misoprostol Oral Tablet (NCT05568745)
- 2026-10-15Results posted on the registry: ACADIA Pharmaceuticals Inc., Carbetocin + Placebo (NCT06173531)
- 2026-09-04Also stopped (terminated): Aalto University, a drug against OXTR (NCT07214948)
- 2026-08-17Also stopped (terminated): ACADIA Pharmaceuticals Inc., Carbetocin (NCT06420297)
- 2026-07-02Also stopped (suspended): Icahn School of Medicine at Mount Sinai, 40 IU Intranasal Oxytocin + Placebo (NCT02225600)
- 2026-06-11Results posted on the registry: University of Washington, Oxytocin nasal spray or placebo (NCT05968651)
- 2026-03-27Also stopped (terminated): Assistance Publique - Hôpitaux de Paris, Misoprostol (NCT01113229)
- 2026-03-11Results posted on the registry: VA Office of Research and Development, Oxytocin (NCT04228289)
- 2026-02-23Results posted on the registry: University of Florida, Oxytocin (OT) + Placebo (P) (NCT03878589)
- 2026-01-26Also stopped (terminated): Baylor Research Institute, Pitocin (NCT02910115)
- 2026-01-20Results posted on the registry: VA Office of Research and Development, Oxytocin + Placebo (NCT03900754)
- 2026-01-20Also stopped (terminated): VA Office of Research and Development, Oxytocin + Placebo (NCT03900754)
- 2026-01-09Results posted on the registry: The University of Texas Medical Branch, Galveston, Oxytocin (Low dose) + Oxytocin (High dose) (NCT05782816)
- 2025-10-28Results posted on the registry: Wake Forest University Health Sciences, Oxytocin (NCT05929339)
- 2025-10-16Results posted on the registry: Brigham and Women's Hospital, 15-methyl prostaglandin F2α + Methylergonovine Maleate (NCT03584854)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision